Target entity 1 - KAI Research (KAI is a US based niche Full service CRO and health research company)
Objective - With this acquisition, TAKE acquires Phase II and Ill capabilities in North America adding to its current service offerings in Europe & Asia. The company has some differentiated offerings by way of patient registries and e-clinical solutions KAI strengthens our therapeutic expertise mental health, musculoskeletal diseases, CNS, infectious diseases, Oncology and medical devices. The target has long-standing relationships with clinical sites and trusted network of service providers.
The acquisition is expected to close by January 2019, subject to customary closing conditions.
The total consideration for transaction shall be up to USD 27 million, including contingent payments subject to certain financial milestones.
Target entity 2 - DataCeutics (DataCeutics is a specialty Clinical Functional Service Provider based in the USA, headquartered in Philadelphia, USA)
Also Read
Objective - This acquisition strengthens TAKE's domain strength in Data Sciences specific to Life Sciences enabling it to partner with the company's clients providing much higher value adds in their Go-ToMarket strategy in terms of time, technology, and ease of change management to pharma & biotech companies that need to embrace emerging data sources that need a higher level of digital maturity.
The acquisition is expected to close by February 2019, subject to customary closing conditions.
The total consideration for this transaction shall be up to USO 45 million, including contingent payments subject to certain financial milestones.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
